Specifically, NTRK3 mutations were discovered in 229 patients and associated with robust anti-cancer activities in terms of ORR (45.4% vs. 28.3%; P < 0.001), PFS (HR = 0.72; 95% CI, 0.58–0.89; P = 0.01), and OS (HR = 0.60; 95% CI, 0.50–0.73; P < 0.001) (Suppl Fig. 1). Here, NTRK3 is linked to cancer.